ReviewCurrent oncology reports2017
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.
Review in Current oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- KDM6B inhibition enhances chemotherapeutic response in small cell lung cancer via epigenetic regulation of apoptosis and ferroptosis.Cell & bioscience · 2025Article
- Review
- BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancer.Cell death & disease · 2024Article
- The role of alternative splicing in lung cancer.Cancer chemotherapy and pharmacology · 2023Review
- Signal pathways and precision therapy of small-cell lung cancer.Signal transduction and targeted therapy · 2022Review
- Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review.Anti-cancer drugs · 2022Article
- [Immunotherapy Advances in Small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.The oncologist · 2019Review
- Article
- Features and therapeutic potential of T-cell receptors in high-grade glioma.Chinese medical journal · 2019Article
- DLL3: an emerging target in small cell lung cancer.Journal of hematology & oncology · 2019Review
- Novel insights into the role of aptamers in the fight against cancer.Journal of cancer research and clinical oncology · 2019Review
- New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.Journal of experimental & clinical cancer research : CR · 2019Review
- Article
- The 180 splice variant of NCAM-containing exon 18-is specifically expressed in small cell lung cancer cells.Translational lung cancer research · 2018Article
- Immune checkpoint inhibitors and small cell lung cancer: what's new?Journal of thoracic disease · 2018Review
- Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models.Translational lung cancer research · 2018Review
- Tumor heterogenicity: multiple needle biopsies from different lesion sites-key to successful targeted therapy and immunotherapy.Translational lung cancer research · 2018Article
- EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.Journal of the American Society of CytopathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Small cell lung cancer (SCLC) is a devastating and aggressive neuroendocrine carcinoma of the lung. It accounts for ~15% of lung cancer mortality and has had no improvement in standard treatment options for nearly 30 years. However, there is now hope for change with new therapies and modalities of therapy. Immunotherapies and checkpoint inhibitors are entering clinical practice, selected targeted therapies show promise, and "smart bomb"-based drug/radioconjugates have led to good response in early clinical trials. Additionally, new research insights into the genetics and tumor heterogeneity of SCLC alongside the availability of new tools such as patient-derived or circulating tumor cell xenografts offer the potential to shine light on this beshadowed cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.